Joshua D. Lee

Joshua D. Lee, MD

Professor, Department of Population Health

Professor, Department of Medicine

Keywords
addiction, alcohol, criminal justice, primary care, opioid pharmacotherapy, naltrexone, buprenorphine
Summary

Joshua D. Lee, MD, MSc, is a Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Grossman School of Medicine and Director of the ACGME-accredited Addiction Medicine Fellowship. He is a clinician–researcher focused on addiction pharmacotherapies in primary care and criminal justice populations.  He has conducted multiple NIH clinical trials examining the use of naltrexone and buprenorphine opioid and alcohol treatments in community criminal justice involved adults, at release from jail, and within community primary care settings. He leads the NYU Langone 'Hub' of the National Institute on Drug Abuse Justice and Community Outcomes and Innovation Network (JCOIN).

Phone

646-501-3552

Fax

646-501-2706

Academic office

180 Madison Ave

17th Floor, 1714

New York, NY 10016

Lab Website
Lee Lab
Is this your profile?
Edit profile

These focus areas and their associated publications are derived from medical subject headings from PubMed.
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

Positions

Professor, Department of Population Health at NYU Grossman School of Medicine

Professor, Department of Medicine at NYU Grossman School of Medicine

Co- Director, Section on Tobacco, Alcohol, and Drug Use

Director, NYU Fellowship in Addiction Medicine

Graduate Education

MD from University of Tennessee

Residency And Fellowship Training

Residency, NYU/Bellevue, Internal Medicine - Primary Care

Residency, NYU/Bellevue, Internal Medicine - Primary Care

Postdoctoral Training

Weill Cornell Medicine - Graduate School of Medical Science, Fellowship in Health Service Research and Clinical Epidemiology

Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT CJS)

Effectiveness and impact of counseling enhanced with electronic cigarettes for harm reduction in smokers with opioid use disorder

Can a radical transformation of preventive care reduce mortality by 20% in low SES populations? Preparatory work focusing on AUD/heavy alcohol use HIV risk and cardiovascular risk.

See All Studies (3)

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Lee, Joshua D; Nunes, Edward V Jr; Novo, Patricia; Bachrach, Ken; Bailey, Genie L; Bhatt, Snehal; Farkas, Sarah; Fishman, Marc; Gauthier, Phoebe; Hodgkins, Candace C; King, Jacquie; Lindblad, Robert; Liu, David; Matthews, Abigail G; May, Jeanine; Peavy, K Michelle; Ross, Stephen; Salazar, Dagmar; Schkolnik, Paul; Shmueli-Blumberg, Dikla; Stablein, Don; Subramaniam, Geetha; Rotrosen, John

Lancet. 2018 01 27; 391(10118):309-318

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders

Lee, Joshua D; Friedmann, Peter D; Kinlock, Timothy W; Nunes, Edward V; Boney, Tamara Y; Hoskinson, Randall A Jr; Wilson, Donna; McDonald, Ryan; Rotrosen, John; Gourevitch, Marc N; Gordon, Michael; Fishman, Marc; Chen, Donna T; Bonnie, Richard J; Cornish, James W; Murphy, Sean M; O'Brien, Charles P

New England journal of medicine. 2016 Mar 31; 374(13):1232-42

Public sector low threshold office-based buprenorphine treatment: outcomes at year 7

Bhatraju, Elenore Patterson; Grossman, Ellie; Tofighi, Babak; McNeely, Jennifer; DiRocco, Danae; Flannery, Mara; Garment, Ann; Goldfeld, Keith; Gourevitch, Marc N; Lee, Joshua D

Addiction science & clinical practice. 2017 02 28; 12(1):7

Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC)

Clayman, Nancy; Eamranond, Pracha; Hanks, Helen; Mitcheff, Michael; RappaMannion, Lisa; York, Diane; Mattis, Paula; Guinen, Heidi; Carp, Alex; Olson, Laura; Bell, Kathleen; Shahi, Lydia; Saunders, Elizabeth; Lee, Joshua; Marsch, Lisa

Health & justice. 2025 Apr 08; 13(1):22

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data

Lodi, Sara; Yan, Shapei; Bovell-Ammon, Benjamin; Christine, Paul J; Hsu, Heather E; Bernson, Dana; Novo, Patricia; Lee, Joshua D; Rotrosen, John; Liebschutz, Jane M; Walley, Alexander Y; Larochelle, Marc R

Addiction (Abingdon, England). 2025 Mar 19;

Dissemination of health content through social networks: YouTube and opioid use disorders

O'Kelly, Bridget; Holmes, Perry; Cheng, Anna; Lee, Joshua D; Tofighi, Babak

Journal of substance use & addiction treatment. 2024 Oct; 165:209475

Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study

Krawczyk, Noa; Lim, Sungwoo; Cherian, Teena; Goldfeld, Keith S; Katyal, Monica; Rivera, Bianca D; McDonald, Ryan; Khan, Maria; Wiewel, Ellen; Braunstein, Sarah; Murphy, Sean M; Jalali, Ali; Jeng, Philip J; Kutscher, Eric; Khatri, Utsha G; Rosner, Zachary; Vail, William L; MacDonald, Ross; Lee, Joshua D

Drug & alcohol dependence. 2024 Aug 01; 261:111377

Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder

Christine, Paul J; Lodi, Sara; Hsu, Heather E; Bovell-Ammon, Benjamin; Yan, Shapei; Bernson, Dana; Novo, Patricia; Lee, Joshua D; Rotrosen, John; Liebschutz, Jane; Walley, Alexander Y; Larochelle, Marc R

Addiction. 2024 Jul; 119(7):1313-1321

See All Publications (127)

Read Story
Read Story
Read Story
Read Story